Compare Novartis with UNIPHOS ENT - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NOVARTIS vs UNIPHOS ENT - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NOVARTIS UNIPHOS ENT NOVARTIS/
UNIPHOS ENT
 
P/E (TTM) x 86.7 13.8 627.8% View Chart
P/BV x 2.7 0.3 956.3% View Chart
Dividend Yield % 1.3 3.1 41.5%  

Financials

 NOVARTIS   UNIPHOS ENT
EQUITY SHARE DATA
    NOVARTIS
Mar-21
UNIPHOS ENT
Mar-21
NOVARTIS/
UNIPHOS ENT
5-Yr Chart
Click to enlarge
High Rs77090 851.8%   
Low Rs50137 1,354.1%   
Sales per share (Unadj.) Rs154.50.1 128,959.9%  
Earnings per share (Unadj.) Rs8.53.5 240.8%  
Cash flow per share (Unadj.) Rs13.43.5 380.3%  
Dividends per share (Unadj.) Rs10.003.40 294.1%  
Avg Dividend yield %1.65.3 29.5%  
Book value per share (Unadj.) Rs289.2390.3 74.1%  
Shares outstanding (eoy) m24.6969.55 35.5%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x4.1532.0 0.8%   
Avg P/E ratio x75.118.1 414.4%  
P/CF ratio (eoy) x47.518.1 262.3%  
Price / Book Value ratio x2.20.2 1,346.4%  
Dividend payout %118.196.7 122.2%   
Avg Mkt Cap Rs m15,6914,430 354.2%   
No. of employees `000NANA-   
Total wages/salary Rs m1,08518 6,144.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m3,8148 45,780.3%  
Other income Rs m332265 125.3%   
Total revenues Rs m4,146273 1,516.9%   
Gross profit Rs m267-31 -870.8%  
Depreciation Rs m1220 34,742.9%   
Interest Rs m770-   
Profit before tax Rs m400234 171.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m191-11 -1,815.9%   
Profit after tax Rs m209245 85.5%  
Gross profit margin %7.0-367.9 -1.9%  
Effective tax rate %47.8-4.5 -1,061.7%   
Net profit margin %5.52,935.3 0.2%  
BALANCE SHEET DATA
Current assets Rs m9,224606 1,521.8%   
Current liabilities Rs m3,5733 135,325.8%   
Net working cap to sales %148.27,244.4 2.0%  
Current ratio x2.6229.6 1.1%  
Inventory Days Days1761,205,787 0.0%  
Debtors Days Days370-  
Net fixed assets Rs m2,48027,110 9.1%   
Share capital Rs m123139 88.7%   
"Free" reserves Rs m7,01827,008 26.0%   
Net worth Rs m7,14127,147 26.3%   
Long term debt Rs m00-   
Total assets Rs m11,70327,716 42.2%  
Interest coverage x6.2NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.30 108,418.4%   
Return on assets %2.40.9 276.8%  
Return on equity %2.90.9 324.9%  
Return on capital %6.70.9 775.3%  
Exports to sales %9.30-   
Imports to sales %00-   
Exports (fob) Rs m354NA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3540-   
Fx outflow Rs m9740 1,948,520.0%   
Net fx Rs m-6210 1,241,380.0%   
CASH FLOW
From Operations Rs m-692-46 1,508.8%  
From Investments Rs m952-339 -281.0%  
From Financial Activity Rs m-368NA-  
Net Cashflow Rs m-109-384 28.2%  

Share Holding

Indian Promoters % 0.0 73.8 -  
Foreign collaborators % 70.7 0.0 -  
Indian inst/Mut Fund % 0.8 15.4 5.3%  
FIIs % 0.0 15.4 0.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.3 26.2 111.8%  
Shareholders   45,141 12,335 366.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NOVARTIS With:   ELEGANT FLOR  CHD CHEMICALS  VAXTEX COTFAB  ICVL STEELS  BHILWARA SP.  



Today's Market

India's Fiscal Deficit, Anand Rathi Wealth IPO, and Buzzing Stocks Today(Pre-Open)

Indian share markets ended on a negative note yesterday. Benchmark indices edged lower as global cues turned bearish after US pharma.

Related Views on News

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

Block Deal Disappoints Max Healthcare Shareholders. Stock Falls 6% (Views On News)

Sep 30, 2021

The divestment of 6.6% stake by the promoter is considered to be one of the largest block deals of the market.

5 Indian Pharma Companies Riding the Vaccination Wave (Views On News)

Sep 3, 2021

These companies are likely to benefit the most from Covid-19 vaccines.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

How to Find Your Next 10-Bagger in this Market(Profit Hunter)

Nov 19, 2021

The #1 make or break factor in your portfolio you shouldn't ignore.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing.(Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NOVARTIS SHARE PRICE


Nov 30, 2021 (Close)

TRACK NOVARTIS

  • Track your investment in NOVARTIS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NOVARTIS - EARUM PHARMACEUTICALS COMPARISON

COMPARE NOVARTIS WITH

MARKET STATS